Receipt of national comprehensive cancer network guideline-concordant prostate cancer care among african american and caucasian american men in north carolina

Cancer

Volumn 119, Issue 12, 2013, Pages 2282-2290

  Ellis, Shellie D ^a   Blackard, Bonny ^b,c   Carpenter, William R ^a,c   Mishel, Merle ^c   Chen, Ronald C ^b,c   Godley, Paul A ^b,c   Mohler, James L ^d   Bensen, Jeannette T ^a,c  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

guideline concordant care; National Comprehensive Cancer Network; North Carolina Health Care Access Project (HCaP NC); prostate cancer; quality of care

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; EUROPEAN AMERICAN; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; TREATMENT OUTCOME; UNITED STATES;

AFRICAN AMERICANS; COMPREHENSIVE HEALTH CARE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GUIDELINE ADHERENCE; HEALTHCARE DISPARITIES; HUMANS; MALE; MIDDLE AGED; NORTH CAROLINA; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOCIOECONOMIC FACTORS;

EID: 84878615482     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28004     Document Type: Article

References (34)

1. Barocas DA, Penson DF,. Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int. 2010; 106: 322-328.
2. Morris CR, Snipes KP, Schlag R, Wright WE,. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control. 1999; 10: 503-511.
3. Schymura MJ, Kahn AR, German RR, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer. 2010; 10: 152.
4. Spencer BA, Miller DC, Litwin MS, et al. Variations in quality of care for men with early-stage prostate cancer. J Clin Oncol. 2008; 26: 3735-3742.
5. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF,. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004; 64: 1171-1176.
6. Carson AP, Howard DL, Carpenter WR, et al. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer. J Pain Symptom Manage. 2010; 39: 872-881.
7. Shahinian VB, Kuo YF, Gilbert SM,. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010; 363: 1822-1832.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Fort Washington, PA; National Comprehensive Cancer Network; 2010. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp.
9. Wilt TJ, Shamliyan T, Taylor B, et al. Comparative effectiveness of therapies for clinically localized prostate cancer. Comparative Effectiveness Review No. 13. Rockville, MD: Agency for Healthcare Research and Quality; February 2008.
10. National Comprehensive Cancer Network. Prostate Cancer. In: NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA; National Comprehensive Cancer Network; 2004. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp.
11. Andersen RM, Davidson PL, Ganz PA,. Symbiotic relationships of quality of life, health services research and other health research. Qual Life Res. 1994; 3: 365-371.
12. Sadetsky N, Lubeck DP, Latini DM, et al. Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: data from caPSURE. Manag Care Interface. 2005; 18: 25-30.
13. Talcott JA, Spain P, Clark JA, et al. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer. 2007; 109: 1599-1606.
14. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008; 58: 9-31.
15. Schroeder JC, Bensen JT, Su LJ, et al. The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. Prostate. 2006; 66: 1162-1176.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
17. LaVeist TA, Nickerson KJ, Bowie JV,. Attitudes about racism, medical mistrust, and satisfaction with care among African American and white cardiac patients. Med Care Res Rev. 2000; 57 (suppl 1): 146-161.
18. LaVeist TA, Isaac LA, Williams KP,. Mistrust of health care organizations is associated with underutilization of health services. Health Serv Res. 2009; 44: 2093-2105.
19. Stata/IC 11.2 for Windows [computer program]. College Station, TX: StataCorp LP; 2011.
20. Gross CP, Smith BD, Wolf E, Andersen M,. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008; 112: 900-908.
21. Chen RC, Carpenter WR, Hendrix LH, et al. Racial Differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer, a population-based study. American Society of Clinical Oncology. Chicago, IL. J Clin Oncol. 2010: abstr 9002.
22. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW,. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827.
23. Conti PD, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ,. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev. 2007;(4): CD005009.
24. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
25. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173. 108th Congress (2003).
26. Dinan MA, Robinson TJ, Zagar TM, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys. 2012; 82: e781-e786.
27. Bahnson RR, Hanks GE, Huben RP, et al. National Comprehensive Cancer Network. NCCN practice guidelines for prostate cancer. Oncology (Williston Park). 2000; 14: 111-119.
28. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006; 98: 839-845.
29. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS,. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol. 2007; 25: 5359-5365.
30. Institute of Medicine, Committee on Cancer Research Among Minorities and the Medically Underserved. The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved. Washington, DC: The National Academies Press; 1999.
31. State Center for Health Statistics and Office of Minority Health and Health Disparities. North Carolina Minority Health Facts: 2005. African Americans. Raleigh, NC: Department of Health and Human Services; 2005.
32. Sarrazin MS, Campbell ME, Richardson KK, Rosenthal GE,. Racial segregation and disparities in health care delivery: conceptual model and empirical assessment. Health Serv Res. 2009; 44: 1424-1444.
33. Jayadevappa R, Malkowicz SB, Chhatre S, Gallo J, Schwartz JS,. Racial and ethnic variation in health resource use and cost for prostate cancer. BJU Int. 2010; 106: 801-808.
34. Parsons JK, Kwan L, Connor SE, Miller DC, Litwin MS,. Prostate cancer treatment for economically disadvantaged men: a comparison of county hospitals and private providers. Cancer. 2010; 116: 1378-1384.